Amarin Corporation, CRISPR Therapeutics, and Geron Corporation could all see big gains next week

With numerous clinical and regulatory catalysts on the near-term horizon, biotech stocks should finish the year in strong fashion. This month, for instance, Amarin Corp. (NASDAQ:AMRN), CRISPR Therapeutics (NASDAQ:CRSP), and Geron Corp. (NASDAQ:GERN) are all slated to roll out big news that may shape the industry's outlook for the remainder of the year.